Floatz logo

Alpelisib

Head and Neck Squamous Cell Carcinoma

The Methodist Hospital Research InstituteSmall moleculePhase 1Dormant
CC
40/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
65/ 100

Competitive context

130 Active assets in the Head and Neck Squamous Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
UNC Lineberger Comprehensive Cancer Center
Phase 4BB
Pembrolizumab
UNC Lineberger Comprehensive Cancer Center
Phase 4BB
Epirubicin
UNC Lineberger Comprehensive Cancer Center
Phase 4BB
Cetuximab
Fate Therapeutics
Phase 3B
Docetaxel
National Cancer Institute (NCI)
Phase 3B

View all 50 →

Same molecule, other indications

Alpelisib is also rated in:

triple-negative breast carcinomaDormant
BB
Indicative ·
67 / 100
View asset →
HER2 positive breast carcinomaDormant
BB
Indicative ·
66 / 100
View asset →
Sickle Cell AnemiaDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →